Prostate cancer

An evolving paradigm

Jorge R. Caso, Vladimir Mouraviev, Matvey Tsivian, Thomas J. Polascik, Judd W. Moul

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

Original languageEnglish
Pages (from-to)805-809
Number of pages5
JournalJournal of Endourology
Volume24
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Prostatic Neoplasms
Prostate-Specific Antigen
Tumor Burden
Recurrence
Health
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Caso, J. R., Mouraviev, V., Tsivian, M., Polascik, T. J., & Moul, J. W. (2010). Prostate cancer: An evolving paradigm. Journal of Endourology, 24(5), 805-809. https://doi.org/10.1089/end.2009.0539

Prostate cancer : An evolving paradigm. / Caso, Jorge R.; Mouraviev, Vladimir; Tsivian, Matvey; Polascik, Thomas J.; Moul, Judd W.

In: Journal of Endourology, Vol. 24, No. 5, 01.05.2010, p. 805-809.

Research output: Contribution to journalArticle

Caso, JR, Mouraviev, V, Tsivian, M, Polascik, TJ & Moul, JW 2010, 'Prostate cancer: An evolving paradigm', Journal of Endourology, vol. 24, no. 5, pp. 805-809. https://doi.org/10.1089/end.2009.0539
Caso JR, Mouraviev V, Tsivian M, Polascik TJ, Moul JW. Prostate cancer: An evolving paradigm. Journal of Endourology. 2010 May 1;24(5):805-809. https://doi.org/10.1089/end.2009.0539
Caso, Jorge R. ; Mouraviev, Vladimir ; Tsivian, Matvey ; Polascik, Thomas J. ; Moul, Judd W. / Prostate cancer : An evolving paradigm. In: Journal of Endourology. 2010 ; Vol. 24, No. 5. pp. 805-809.
@article{660a9730c1d7433596bdf585537b924d,
title = "Prostate cancer: An evolving paradigm",
abstract = "Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.",
author = "Caso, {Jorge R.} and Vladimir Mouraviev and Matvey Tsivian and Polascik, {Thomas J.} and Moul, {Judd W.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1089/end.2009.0539",
language = "English",
volume = "24",
pages = "805--809",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Prostate cancer

T2 - An evolving paradigm

AU - Caso, Jorge R.

AU - Mouraviev, Vladimir

AU - Tsivian, Matvey

AU - Polascik, Thomas J.

AU - Moul, Judd W.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

AB - Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.

UR - http://www.scopus.com/inward/record.url?scp=77952554715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952554715&partnerID=8YFLogxK

U2 - 10.1089/end.2009.0539

DO - 10.1089/end.2009.0539

M3 - Article

VL - 24

SP - 805

EP - 809

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 5

ER -